Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K)

被引:0
|
作者
Saad, Abdulaziz Ahmed A. [1 ]
Zhang, Fan [2 ]
Mohammed, Eyad Abdulwhab H. [1 ]
Wu, Xin'an [2 ]
机构
[1] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Peoples R China
[2] Lanzhou Univ, Hosp 1, Dept Pharm, Lanzhou 730000, Peoples R China
关键词
drug-drug interaction; nephrotoxicity; organic cation transporter 2; multidrug and toxin extrusion 1 and 2-K; CISPLATIN-INDUCED NEPHROTOXICITY; SOLUTE CARRIER TRANSPORTERS; EXTRUSION PROTEINS; KIDNEY INJURY; TARGETED DISRUPTION; GENETIC-VARIANTS; METFORMIN; MATE1; CIMETIDINE; PHARMACOKINETICS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The organic cation transporter 2 (OCT2) belongs to the SLC22 family, while the multidrug and toxin extrusion 1 and 2-K (1VIATE1/MATE2-K) belong to the SLC47 family, are localized to the basolateral and apical membrane of human renal proximal tubular epithelial cells, respectively. They are polyspecific transporters that enable the transit of structurally diversified drugs with overlapping selectivity across plasma membranes. OCT2 and MATE1/2-K are critically involved in renal secretion, pharmacokinetics (PK), and toxicity of cationic drugs. Drug-drug interactions (DDIs) at OCT2 and/or MATEI/2-K have been shown to result in clinical impacts on PK, therapeutic efficacy and are probably involved in the renal accumulation of drugs. Sites of OCT2 and MATE1/2-K expression and function play an essential role in the pharmacokinetics and toxicity of drugs, such as cisplatin. Thus, knowing the sites (basolateral vs. apical) of the interaction of two drugs at transporters is essential to understanding whether this interaction helps prevent or enhance drug-induced nephrotoxicity. In this work, an overview of OCT2 and MATE1/2-K is presented. Primary structure, membrane location, functional properties, and clinical impact of OCT2 and MATE1/2-K are presented. In addition, clinical aspects of DDIs in OCT2 and MATE1/2-K and their involvement in drug nephrotoxicity are compiled.
引用
收藏
页码:382 / 393
页数:12
相关论文
共 50 条
  • [21] Functional characterization of amino acid variants of H+/organic cation antiporters (MATE1 and MATE2-K)
    Kajiwara, Moto
    Terada, Tomohiro
    Ogasawara, Ken
    Iwano, Junko
    Katsura, Toshiya
    Inui, Ken-ichi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 : 52 - 52
  • [22] Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K
    Motohashi, Hideyuki
    Inui, Ken-ichi
    MOLECULAR ASPECTS OF MEDICINE, 2013, 34 (2-3) : 661 - 668
  • [23] No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches
    Nguyen, Dung
    Miao, Xiusheng
    Taskar, Kunal
    Magee, Mindy
    Gorycki, Pete
    Moore, Katy
    Tai, Guoying
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [24] Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients
    Toyama, Kana
    Yonezawa, Atsushi
    Tsuda, Masahiro
    Masuda, Satohiro
    Yano, Ikuko
    Terada, Tomohiro
    Osawa, Riyo
    Katsura, Toshiya
    Hosokawa, Masaya
    Fujimoto, Shimpei
    Inagaki, Nobuya
    Inui, Ken-Ichi
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (02): : 135 - 138
  • [25] Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
    Gruen, Barbara
    Kiessling, Michael K.
    Burhenne, Juergen
    Riedel, Klaus-Dieter
    Weiss, Johanna
    Rauch, Geraldine
    Haefeli, Walter E.
    Czock, David
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 787 - 796
  • [26] Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects
    Hsueh, Chia-Hsiang
    Anderson, Kacey
    Shen, Gong
    Yun, Chohee
    Qin, Ann
    Othman, Ahmed A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 361 - 370
  • [27] Mirogabalin, a novel α2δ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K
    Yamamura, Naotoshi
    Mikkaichi, Tsuyoshi
    Itokawa, Ken-Ichi
    Hoshi, Misa
    Damme, Katja
    Geigner, Stefanie
    Baumhauer, Christine
    XENOBIOTICA, 2022, 52 (9-11) : 997 - 1009
  • [28] In vitro analysis of new putative biomarkers for OCT2/MATE-mediated renal drug-drug interactions
    Picurova, J.
    Mueller, F.
    Koenig, J.
    Stopfer, P.
    Fromm, M. F.
    Gessner, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S35 - S36
  • [29] Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach
    Mathialagan, Sumathy
    Feng, Bo
    Rodrigues, A. David
    Varma, Manthena V. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 855 - 859
  • [30] A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions
    Tuerk, Denise
    Hanke, Nina
    Lehr, Thorsten
    PHARMACEUTICS, 2020, 12 (11) : 1 - 19